Head-To-Head Analysis: SiBone (NASDAQ:SIBN) versus Envista (NYSE:NVST)

Envista (NYSE:NVST) and SiBone (NASDAQ:SIBN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Insider and Institutional Ownership

98.1% of SiBone shares are owned by institutional investors. 1.0% of Envista shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Envista and SiBone, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0	11	6	0	2.35
SiBone	1	0	6	0	2.71

Envista currently has a consensus price target of $28.86, indicating a potential upside of 27.15%. SiBone has a consensus price target of $24.50, indicating a potential upside of 21.25%. Given Envista’s higher possible upside, research analysts clearly believe Envista is more favorable than SiBone.

Valuation & Earnings

This table compares Envista and SiBone”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72 billion	1.34	$47.00 million	$0.58	39.13
SiBone	$200.93 million	4.46	-$18.90 million	($0.34)	-59.43

Envista has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Envista has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, SiBone has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Profitability

This table compares Envista and SiBone’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envista	3.33%	7.88%	4.33%
SiBone	-6.85%	-8.23%	-6.07%

Summary

Envista beats SiBone on 9 of the 13 factors compared between the two stocks.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.